Sionna Therapeutics (SION) Equity Average (2024 - 2026)

Sionna Therapeutics has disclosed Equity Average across 3 years of filings, most recently posting $297.5 million for Q1 2026.

• Equity Average for Q1 2026 came in at $297.5 million, up 216.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $297.5 million (up 216.42% YoY), and the FY2025 annual result was $71.6 million, changed N/A from the prior year.
• Equity Average came in at $297.5 million for Q1 2026 at Sionna Therapeutics, down from $314.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $344.1 million in Q2 2025 to a low of -$156.1 million in Q4 2024.
• The 3-year median for Equity Average is $195.8 million (2025), against an average of $119.0 million.
• Across the five-year window, Equity Average surged 364.84% in 2025 and surged 216.42% in 2026, its largest moves.
• Sionna Therapeutics' Equity Average stood at -$156.1 million in 2024, then surged by 301.27% to $314.3 million in 2025, then decreased by 5.32% to $297.5 million in 2026.
• The last three Equity Average figures came in at $297.5 million (Q1 2026), $314.3 million (Q4 2025), and $329.0 million (Q3 2025), per Business Quant data.